Denali Therapeutics Inc. (DNLI) Tops Q1 EPS by 2c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.68), $0.02 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c
• Evolution Petroleum launches stock offering to fund Permian Basin deal